245429-73-6Relevant articles and documents
Application of polyamines and amino acid derivatives based on 2-azabicycloalkane backbone in enantioselective aldol reaction
Iwan, Dominika,Kamińska, Karolina,Wojaczyńska, El?bieta
, (2021/09/04)
Carbon–carbon bond forming reactions, such as aldol reaction and condensation, belong to extremely desired transformations as manifested by >25,000 entries in SciFinder. Their stereoselective variant requires the use of an appropriate catalyst with a stri
Substituted phenoxy-2-azabicyclo[3.2.1]octane compound as well as preparation method and application thereof
-
Paragraph 0055; 0058-0059, (2020/06/02)
The invention belongs to the technical field of medicines, and particularly relates to a substituted phenoxy-2-azabicyclo[3.2.1]octane compound as well as a preparation method and application thereof.The general structural formula I of the substituted phenoxy-2-azabicyclo[3.2.1]octane compound is specifically shown in the specification, wherein R is methyl, methoxy, cyano, fluorine, chlorine, bromine or nitro groups. Pharmacological research shows that the compound shows a good effect in an in-vitro antitumor activity test, and can be used for preparing antitumor drugs. The preparation methodof the substituted phenoxy-2-azabicyclo [3.2.1]octane compound provided by the invention is simple and feasible, relatively high in yield and easy for large-scale production.
KRAS G12C INHIBITORS
-
Paragraph 0372, (2020/07/25)
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
ALKYNE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is alkyne substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein can reduce the excessive activation of complement.
COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
-
, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
AMIDE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein are capable of reducing the excessive activation of complement.
ETHER COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
Substituted piperidine amide derivative, preparation method thereof, and application of derivative to pharmacy
-
, (2017/08/30)
The invention relates to a substituted piperidine amide derivative as shown in a general formula (I) or a stereisomer and pharmaceutically acceptable salt thereof, a preparation method of the derivative, medicinal combination as well as application of the derivative to the aspects of local anaesthesia or analgesia. The definition of each group of the general formula (I) is consistent with that of the description. (The general formula (I) is as shown in the description).
AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
Paragraph 0576; 0579; 0580, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
